Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Q1 Earnings Call Highlights
Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma.
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $1 per share a year ago.
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why
Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%
The mean of analysts' price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript
Verrica Pharmaceuticals Inc. ( VRCA ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Jayson Rieger - President, CEO & Director John Kirby - Interim Chief Financial Officer Conference Call Participants Kevin Gardner Stacy Ku - TD Cowen, Research Division Yuchen Ding - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Third Quarter 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jayson M. Rieger - President, CEO & Director John J.
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
Verrica Pharmaceuticals Inc. (VRCA) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.7 per share. This compares to a loss of $3.1 per share a year ago.
Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2025 Corporate Update Conference Call May 13, 2025 4:30 PM ET Company Participants Kevin Gardner - Managing Director LifeSci Advisors Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Serge Belanger - Needham and Company Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' First Quarter 2025 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.38 per share a year ago.
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
